Objective: We report our experience with the use of a left ventricular assist device (LVAD) as destination therapy (DT) for the management of patients with cardiac end-stage dystrophinopathies.
Results: All patients survived to hospital discharge. The early postoperative course was characterized by abdominal bleeding (1 patient) and retropharyngeal bleeding (1 patient). Because of abdominal or retropharyngeal bleeding, both required postoperative heparin infusion discontinuation for 35 and 33 days, respectively. Among the late complications, 1 child developed osteolysis and infection at the pedestal site of the device, which required surgical displacement; 1 patient required gastrostomy as a result of poor feeding, and another had a cerebral stroke, which was treated with percutaneous thrombus aspiration. The other 2 patients did not show early or late complications. At a median follow-up time of 21.7 months (range, 3-45 months) there have been 3 deaths: 1 patient died of a lung infection after 45 months, 1 died of tracheal bleeding after 29 months, and 1 died of cerebral hemorrhage after 14 months.
Conclusions:
Our experience indicates that the use of an LVAD as DT in patients with dystrophinopathies with end-stage DCM is feasible, suggesting that it may be suitable as a palliative therapy for the treatment of these patients with no other therapeutic options. (J Thorac Cardiovasc Surg 2017;153:669-74)
Patients with LVAD-DMD participate in the hockey wheelchair world championship.
Central Message
Our experience showed the possibility of using a left ventricular assist device as destination therapy in patients with dystrophinopathies with end-stage dilated cardiomyopathy.
Perspective
End-stage cardiomyopathy is the main cause of mortality in patients with dystrophinopathies. These patients present a difficult challenge because every single step is characterized by a fine balance between risks and benefits. Our results suggest that the use of VAD may be considered a palliative therapy ensuring an adequate time-limited quality of life in children with no other therapeutic options.
See Editorial Commentary page 675.
See Editorial page 667.
The dystrophinopathies include a spectrum of muscular dystrophy phenotypes with variable involvement of skeletal and cardiac muscle. 1 Duchenne muscular dystrophy (DMD) is an X-linked muscular disease responsible for over 80% Pneumology Unit -University Hospital Pediatric Department, Bambino Ges u Children Hospital, IRCCS; and of all muscular dystrophies caused by the absence of dystrophin, a protein that links the cytoskeleton to the extracellular matrix. 2 Respiratory failure as a result of respiratory muscle weakness and chest deformity (kyphoscoliosis), along with respiratory infections, has been considered the most common cause of death. 3 Nowadays, with the improvement in ventilatory support, particularly with the use of noninvasive nocturnal ventilation (NIV), the natural history of this disease has changed and cardiac complications such as dilated cardiomyopathy (DCM) have become the main cause of mortality (>40%). 4 DCM in DMD is characterized by a progressive development of fibrosis that extends from the epicardium to the endocardium, starting from the inferior posterior wall down toward the apex and around the heart, 5-7 which allows progressive impairment of the left ventricular ejection fraction until the occurrence of clinical heart failure (HF). There is a higher mortality for DMD cardiomyopathy compared with other DCMs. 8 Several studies have demonstrated that the incidence of DCM in patients with dystrophinopathies increases progressively with age: 25% of patients have cardiomyopathy by the age of 6 years, 9% are affected between 6 and 10 years, and by adulthood (>20 years old) all patients have signs of cardiac impairment. [9] [10] [11] Although heart transplantation (HTx) remains the surgical procedure of choice for children with severe advanced HF, 12, 13 dystrophinopathies have generally been considered a contraindication for HTx because of the possibility of respiratory failure and progressive skeletal myopathy leading to limited functional capacity. 14, 15 An alternative treatment for endstage HF in dystrophinopathies is the use of left ventricular assist devices (LVAD) as destination therapy (DT). We have used the Jarvik 2000 LVAD (Jarvik Heart, Inc, New York); this is a thumb-sized axial flow impeller pump, weighing 90 g, and with a wide displacement volume of 25 cm. 16 The impeller spins within an electromagnetic field of between 8000 and 120,000 rpm, delivering a systemic blood flow of 3-8 L/min depending on the systemic vascular resistance, and with a power consumption of less than 12 W. 17 Recently, our group reported the first case of LVAD as DT in a patient with DMD. 18 In the present study, we report our midterm results with the use of LVAD as DT for the management of end-stage HF in patients with dystrophinopathies.
METHODS
We retrospectively reviewed medical and surgical records, discharge summaries, and clinical follow-up data of all consecutive patients with dystrophinopathies and DCM treated with LVAD at Bambino Ges u Children Hospital in Rome from February 2011 to February 2016. Approval from the Institutional Scientific Board of the Bambino Ges u Children's Hospital was obtained. We collected data on sex, age, and weight at surgery, type of dystrophinopathy, type of surgical approach, intra-and post-operative management, hospital stay, and postoperative complications. All patients were followed by our Out-Patients Heart Failure Service and were admitted to our institution for acute HF. Three patients required noninvasive positive pressure ventilation (NIV) before hospital admission for respiratory impairment. Preoperatively, all were evaluated by a multidisciplinary approach including anesthesiology, cardiology, cardiothoracic surgery, neurology, pulmonology, hematology, ear nose and throat specialists, orthopedic surgery, infectious diseases specialists, psychology, and physiotherapy. Our criteria for choosing patients for LVAD implant are dependence on intravenous inotropic support and a cardiac index <1.5. Otherwise, absolute contraindications are, in addition to those normally used for LVAD surgery, 24 hours of NIV, tracheostomy, and noncompliance of family. All patients were wheelchair dependent, except for 1 who was able to ambulate for a short time without any support. Follow-up was complete in all patients (100%). After LVAD implantation, our followup program provides a cardiologic evaluation once a month, and nutritional and respiratory assessment is performed every 6 months. Median preoperative albumin was 4.3 g/dL (range, 4-4.6 g/dL) and median postoperative albumin was 3.9 g/dL (range, 3.5-4.5 g/dL). The median preoperative total protein value was 7.2 g/dL (range, 7-7.4 g/dL), while the median postoperative value was 7.4 g/dL (range, 6.4-7.9 g/dL). The primary outcomes of our analysis were early and late death defined as any condition related to LVAD implantation that caused death within or after 30 days from surgery, respectively.
Preoperative Assessment
In the preoperative assessment for LVAD surgery, particular care was taken to evaluate right ventricle (RV) function because, as reported elsewhere, 19, 20 RV failure is one of the most important complications of postoperative LVAD implantation. Before surgery in our center, all patients underwent echocardiography, magnetic resonance imaging, right and left catheterization, pulmonary function testing, and full laboratory work-up. A computed tomography scan of the head is routinely performed to assess the area of the skull where the pedestal will be implanted (bone thickness should be at least 4 mm). A multidisciplinary approach taking into account all comorbidities is mandatory to select candidates for LVAD. The central goal of patient-centric care requires that the patient and the family are sufficiently educated about the alternatives available so that their expectations can be met as fully as possible.
Surgical Technique
The first step is the implantation of the titanium pedestal into the skull behind the mastoid access. 21 A periosteal flap is generally carried out in a relatively flat area of the skull where the position of the titanium base has been previously marked. 22 The entry site for the pedestal is covered with an autologous pericardial patch with a central hole to allow the exit of the
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connection tube, and the power cable is tunneled from the mastoid to the mediastinum below the medial part of the sternocleidomastoideus muscle and the anonymous venous trunk. After pedestal implantation, the second step is the insertion of the device. LVAD surgery was performed in all patients through standard median sternotomy on mildly hypothermic cardiopulmonary bypass (CPB). The choice of the LV apex site implantation is made under transesophageal echocardiographic guidance. A special coring knife is inserted through a cruciate incision and, after removal of the myocardial core, the Jarvik 2000 pump is inserted within the LV apex. Subsequently, the outflow graft is routed around the heart over the superior vena cava in the lateral side of the ascending aorta. The outflow graft is covered at the level of the inferior vena cava angle with a Gore-Tex graft (W.L. Gore and Associates, Inc, Flagstaff, Ariz) to avoid compression from the heart. The ascending aorta is partially occluded with a size clamp, and end-to-side anastomosis is performed with a continuous 4-0 Prolene (Ethicon, Inc, Nordersted, Germany) suture. In 1 patient, we used a minimally invasive approach without CPB. A left anterior minithoracotomy on the sixth intercostal space was performed for the intraventricular implantation of the Jarvik 2000, and a subcomplete median sternotomy from the second to the fourth intercostal space (preserving the xiphoid appendage together with the insertion of the rectus abdominis muscles) was carried out for the outflow graft anastomosis to the aorta.
RESULTS
Seven patients with dystrophinopathies and DCM underwent LVAD as DT at our institution during the study period (Table 1) . Based on the primary diagnosis, 6 patients had DMD, and 1 had a b2 sarcoglycan deficit. Median age and weight at surgery were 16.5 years (range, 14.2-23.4 years) and 44 kg (range, 34-70 kg), respectively. Six patients received LVAD after long-term medical intravenous inotropic support, and 1 underwent implantation after 12 days of veno-arterial extracorporeal membrane oxygenation. All patients, preoperatively and after extubation, underwent NIV, cough machine cycles, and a preconditioning cycle with levosimendan 72 hours before Jarvik implantation. Median hospital stay was 77 days (range, 35-180 days). One patient with severe scoliosis experienced, in the early postoperative course, a spleen lesion during the insertion of a chest drain. This led to abdominal bleeding, which required splenectomy and several abdominal surgical revisions. Because of abdominal bleeding, anticoagulation therapy was suspended for 32 days without any pump complications. In another child, on the 13th postoperative day, as a consequence of nasogastric tube placement, severe retropharyngeal bleeding and tongue edema occurred, which required new intubation. A few days later, the presence of a bilateral pleural effusion required the placement of a chest drain, which was complicated by thorax bleeding and a surgical revision was performed. Discontinuation of heparin infusion for 35 days was necessary because of the retropharyngeal bleeding with several otolaryngologic surgical revisions. The same patient developed postoperative gallstones, which were treated by cholecystectomy. Another patient required gastrostomy 10 months after VAD insertion due to poor feeding. After 1 year, the first patient with DMD developed osteolysis and infection at the pedestal site of the device (caused by inappropriate head position during sleep), which required surgical displacement of the pedestal and antibiotic therapy for 6 months (Figure 1 ). Moreover, after 1 year, the patient with the b2 sarcoglycan deficit had a cerebral stroke, which was treated within 3 hours at the Stroke Unit, with percutaneous thrombus aspiration at the cerebral media artery without any neurologic sequelae. The other 2 patients did not show any early or late complications. All patients survived to hospital discharge; however, there were 3 late deaths at a median follow-up time of 22 months (range, 3-45 months): 1 patient died of sepsis due to Staphylococcus aureus lung infection after 45 months; another patient, with a tracheostomy, died in a peripheral hospital of tracheal bleeding due to an inappropriate otorhinolaryngology maneuver after 29 months; and the other died of cerebral hemorrhage after 15 months of LVAD implantation.
DISCUSSION
End-stage cardiomyopathy is one of the complications of dystrophinopathies, leading to progressive left ventricular dysfunction and advanced HF. Until the last decade, respiratory failure that occurred earlier than cardiac failure was the main cause of death. Respiratory care has greatly improved, and DCM is the main cause of morbidity and mortality in patients with DMD up to the third or fourth decade of life. 8 This subgroup of patients currently represents a newly emerging therapeutic challenge. 18 In 2010, The DMD Care Considerations Working Group expanded the existing traditional therapies with novel HF therapies such as mechanical circulatory support and implantable cardioverter-defibrillators for the management of DMD cardiomyopathy. Although the best approach remains unclear, it does seem clear that treatment should be more aggressive. 23 Until now, no definitive therapy has been found to reverse or cure the cardiac and skeletal alterations present in these patients. Although some authors 15 have shown that the long-term clinical outcomes of HTx in selected patients with dystrophinopathies are similar to a matched cohort of patients who undergo transplantation for idiopathic DCM, there is a reluctance to offer cardiac transplantation to these patients with a limited life expectancy in an era of donor shortage. Therefore, the alternative therapeutic option is the use of LVAD. Ryan and colleagues 24 reported their experience with the HeartMate II device in 2 patients with DMD with end-stage DCM. In our group of children, we prefer to use the Jarvik 2000 VAD. The main advantage of this device in DMD wheelchair-dependent patients is related to the positioning of the power cable in the retroauricular site, with a consequently lower risk of infection compared with an abdominal cable. Accurate and appropriate selection of patients DMD suitable for VAD surgery is necessary because this group of patients represents a difficult challenge, where every single step is characterized by a fine balance between the risks and benefits, and different variables play an important role. As previously reported by our group, 25 absolute exclusion criteria are active sepsis, evidence of intrinsic hepatic or renal disease, documented heparin-induced thrombocytopenia, idiopathic purpura, documented coagulopathy, noncompliance of the family, severe respiratory insufficiency (24 hours NIV or tracheostomy), and severe RV dysfunction.
This class of patients requires a series of clinical and surgical precautions and maneuvers that are possible only in centers with a high level of experience of patients with DMD, especially in the postoperative phase. Indeed, according to our experience, the presence of comorbidities such as severe kyphoscoliosis and respiratory muscle weakness, which are common in the patient with advanced DMD, may increase intraoperative risks and postoperative complications. With regard to the surgical technique, we preferred to avoid the left thoracotomy approach, commonly used in adult patients during VAD implantation, because of the respiratory insufficiency of our patients. Moreover, all surgical implantations were performed using CPB except in 1 patient where we performed a minimally invasive off-pump VAD implantation through a left anterior minithoracotomy. This approach allowed us to further reduce postoperative respiratory impairment related to CPB and to a complete sternotomy by preserving the respiratory muscle insertion on the xiphoid process. Similarly, we strongly suggest the use of postoperative NIV because it allows the reduction of postoperative respiratory insufficiency caused by the presence of scoliosis and muscle weakness, through reduction of the work involved in breathing, improvement of alveolar recruitment with better gas exchange, reduction of LV afterload with increasing CO, and by improving hemodynamics. 25 Our experience shows that postoperative care can be extremely challenging and is often burdened by unexpected complications. Severe kyphoscoliosis, resulting in chest deformity and an abnormally elevated diaphragm, needs particular care in routine maneuvers such as chest drain placement because of the potential risk of abdominal organ damage, as happened in our patient. Furthermore, each postoperative cardiac, and especially extracardiac, complication must be managed only in a specialized center because the morbidity and mortality related to inadequate therapeutic maneuvers may be high. Indeed, 1 of our patients died in a peripheral hospital because they underwent bronchoscopic examination with an endoscope that caused severe and intractable retropharyngeal bleeding. Postoperative anticoagulation management may be challenging in patients with DMD. 26 We have developed a standard protocol including attention to intra-and postoperative blood loss, and use of tranexamic acid and prothrombin complexes. 25 However, in the case of postoperative bleeding we have been forced to suspend anticoagulation therapy for 32 or 35 days without VAD function complications. In conclusion, the prolonged life expectancy of patients with DMD up to the third or fourth decade of life incurs the problem of DCM being the main cause of death. Preoperative patient selection and an accurate surgical strategy with multidisciplinary postoperative management are mandatory to ensure good early and midterm results in patients who have DMD with VAD. We show the possibility of using VAD as DT in patients with dystrophinopathies with end-stage DCM to ensure an acceptable quality of life.
According to the basic philosophy of palliative care, which is to achieve the best quality of life for patients even when their illness cannot be cured, 27 our results suggest that the use of VAD as DT may be a palliative, time-limited therapy for the treatment of patients with no other therapeutic options.
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